Hepatocellular carcinoma (HCC) is a male-dominant disease with poor prognosis. Sorafenib is the only approved systemic chemotherapeutic drug for patients with advanced HCC. Previous studies have shown that androgen and androgen receptor (AR) are involved in human hepatocarcinogenesis and the development of HCC. Here, we discuss the recent data on AR and HCC, and the combination of sorafenib and inhibitors of AR for advanced-HCC patients. Androgen-dependent and androgen-independent AR activation exist in human hepatocarcinogenesis. AR could directly control hepatocarcinogenesis and regulate the innate immune system to influence HCC progression. Combination of sorafenib with AR inhibitors might represent a potential treatment for patients with advanced HCC.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2qGhCU9
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
When you make pizza this good you are allowed to brag about it. Come try a square of the best pizza in Erie. Ohhh yeah, we have ice cream no...
-
British Journal of Oral and Maxillofacial Surgery... Stem Cells and DevelopmentMesenchymal Stem/Stroma... [ASAP] Self-Assembly of Giant Mo...
-
Abstract ᅟ http://ift.tt/2pGNeby
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2o6Gupp via IFTTT
-
The efficacy and optimization of poststroke physical therapy paradigms is challenged in part by a lack of objective tools available to resea...
-
Related Articles Exome Sequencing of Oral Squamous Cell Carcinoma Reveals Molecular Subgroups and Novel Therapeutic Opportunities. Th...
-
Related Articles Dumbbell-shaped Jugular Foramen Tumors Extending to the Neck: Surgical Considerations Based on Imaging Findings. Wor...
-
Publication date: Available online 18 January 2017 Source: Free Radical Biology and Medicine Author(s): Philip Wenzel, Sabine Kossmann, Th...
-
Publication date: October 2017 Source: Microbiological Research, Volume 203 from #AlexandrosSfakianakis via Alexandros G.Sfakianakis...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου